Evernorth taps Transcarent for digital cancer program
Evernorth says its Oncology Benefit Services will allow employers to provide a "streamlined" cancer care experience.
Photo: Mo Mo Productions/Getty Images
Evernorth Health Services has selected Transcarent to power its new Oncology Benefit Services program.
The digital platform included in the offering is geared to bring together cancer services across pharmacy and medical benefits and provide more personalized patient support via a dedicated care team.
Evernorth said its Oncology Benefit Services will allow employers to provide a "streamlined" cancer care experience, with all of the benefits and services accessible through a single digital platform.
Members can connect with dedicated American Cancer Society Leadership in Oncology Navigation-credentialed Oncology Nurse Navigators, schedule appointments with oncology Centers of Excellence, connect with virtual urgent care clinicians and receive drug consultations.
WHAT'S THE IMPACT?
Employers are grappling with the impact of cancer on their employees' quality of life, ability to work and wellbeing. Evernorth cited a report showing that cancer has been identified as the top cost driver for employer health plans. And cancer rates for people under the age of 50 continue to increase, according to research published in BMJ.
Through the offering, eligible Evernorth members will have access to a dedicated Oncology Nurse Navigator and care coordinator; support includes answering questions, helping find the right providers, providing educational resources and securing appointments.
They'll also have access to treatment and opinions from quality providers, clinical 24/7 pharmacy support to answer questions about medications via Express Scripts and Accredo, and virtual care from a national network of providers.
Transcarent, said Evernorth, "addresses cancer at every stage, from prevention and screening through survivorship, along with support for caregivers."
This approach drives enhanced quality of life, improved care and increased affordability, said Evernorth.
THE LARGER TREND
Evernorth Health Services is a subsidiary of Cigna. Earlier this year it announced plans to have a Stelara biosimilar available for $0 out-of-pocket for eligible patients of its specialty pharmacy, Accredo, beginning in early 2025.
The interchangeable biosimilar will be produced for Evernorth's affiliate private label distributor, Quallent Pharmaceuticals, and will be available at $0 out-of-pocket for most patients through Quallent's copay assistance program. The program is expected to save individual patients around $4,000 on average per year, according to Evernorth.
Jeff Lagasse is editor of Healthcare Finance News.
Email: jlagasse@himss.org
Healthcare Finance News is a HIMSS Media publication.
